Media Release Sonova proposes Stacy Enxing Seng for election to the Board of Director Staefa (Switzerland), 31 January 2014 - Sonova Holding AG, the world's leading provider of hearing solutions, announces today that its Board of Directors nominates Stacy Enxing Seng as a new board member for election at the next Annual General Meeting in June 2014. Ms. Enxing Seng is currently serving as President of Covidien's global Vascular Therapies business. "We are very pleased to propose Ms. Enxing Seng as a new member to the Board of Directors. Drawing on her impressive track record in growing startups and leading multinational companies, she will be a very important addition to the current Board of Directors. Ms. Enxing Seng's extensive experience in the medtech industry and her commitment to innovation will bring most valuable perspectives to Sonova," says Robert Spoerry, Chairman of the Board of Directors of Sonova Holding AG. Ms. Enxing Seng (born in 1964, US citizen) is currently responsible for managing a global organization of approximately 4,000 employees with $1.6 billion in revenue. She joined Covidien in July 2010 through the ev3 acquisition where she was a founding member and executive officer responsible for leading ev3's peripheral vascular division from inception to a $350 million business. Ms. Enxing Seng has held various positions of increasing responsibility in the healthcare and medtech industry. She received a Master of Business Administration from Harvard University and has a Bachelor of Arts in Public Policy from Michigan State University. "I am delighted to join the Board of Directors of Sonova," said Ms. Enxing Seng. "I have always been passionate about the healthcare and medtech industry, making a difference in the lives of others. I am excited to become part of a growing company which is offering highly innovative products, allowing people with hearing loss to live better lives." - End - Contacts: Investor Relations Media Relations Thomas Bernhardsgrütter Michael Isaac Phone +41 58 928 33 44 Phone +41 58 928 33 24 Mobile +41 79 618 28 07 Mobile +41 79 420 29 56 Email email@example.com Email firstname.lastname@example.org Corinne Hofmann Phone +41 58 928 33 22 Email email@example.com Disclaimer This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Sonova's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sonova undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. About Sonova Sonova Holding AG, headquartered in Staefa, Switzerland, is the leading manufacturer of innovative hearing care solutions. The Group operates through its core business brands Phonak, Unitron, Advanced Bionics and Connect Hearing. Sonova offers its customers one of the most comprehensive product portfolios in the industry - from hearing instruments to cochlear implants to wireless communication solutions. Founded in 1947, the Group is currently present in over 90 countries across the globe and has a workforce of over 9,000 dedicated employees. Sonova generated sales of CHF 1.8 billion in the financial year 2012/13 and a normalized net profit of CHF 309 million. By supporting the Hear the World Foundation, Sonova pursues its vision of a world where everyone enjoys the delight of hearing and therefore lives a life without limitations. For more information please visit www.sonova.com and www.hear-the-world.com. Sonova shares (ticker symbol:SOON, Security no: 1254978, ISIN: CH1012549785) have been listed on the SIX Swiss Exchange since 1994. The securities of Sonova have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or under the applicable securities laws of any state of the United States of America, and may not be offered or sold in the United States of America except pursuant to an exemption from the registration requirements under the U.S. Securities Act and in compliance with applicable state securities laws, or outside the United States of America to non-U.S. Persons in reliance on Regulation S under the U.S. Securities Act. Media Release (PDF) Provider Channel Contact Tensid Ltd., Switzerland newsbox.ch Provider/Channel related enquiries www.tensid.ch www.newsbox.ch firstname.lastname@example.org +41 41 763 00 50
Sonova proposes Stacy Enxing Seng for election to the Board of D
Press spacebar to pause and continue. Press esc to stop.